Search Results
Showing 8 of 8 results
What are Biologics and Biosimilars?
We explain the difference between biologics and biosimilars and showcase Teva’s innovative work in this space
How Can We Use AI to Make Medicines More Efficiently?
Teva’s Chief Medical Officer Eric Hughes outlines the key efficiencies to be gained from artificial intelligence (AI)
Pivot to Growth: The Teva Journey
Mapping the journey of Teva’s Pivot to Growth strategy
"The Three Women Who Inspired Me"
Eric Hughes, Teva Pharmaceuticals Head of Global R&D and Chief Medical Officer, shares stories of the three women who shaped his journey and whose impact has inspired him personally and professionally.
“AI helps us better understand and support patient needs”
Beryl Ojwang, MD, MBA, MPH, Associate Medical Director, Oncology & Biosimilars, North America Medical Affairs, shares how artificial intelligence is bringing patient insights to Teva scientists.
Revolutionary Innovations in Medicine Propelled by AI and Cross-Industry Collaboration
Take a look inside Israel’s AION Labs, which is being supported by Teva to transform the way big pharma works with the aim of discovering new medicines faster, cheaper and more precisely
"What Took Us Years Could Now Take Half the Time": Innovation Is Redefining Pharma
AI and other technologies have significantly shortened the R&D process in the pharma industry. Dr. Eran Harary of Teva Pharmaceuticals sheds light on innovation.
Democratizing Science: Big Pharma Joins Forces with Academia
Building cross-sector and multidisciplinary collaborations, developing innovative technology and supporting the next generation of entrepreneurs will all play an important part in developing the medicines of the future. An industry shift in attitudes and working patterns is needed to embrace this new age and find new ways of operating. At Teva, this shift has already started.
